John Gray

Dr. Gray develops genetic therapies based on parvoviral (AAV) and lentiviral (HIV) vectors. He has contributed significantly to the design, manufacturing, and development of successful treatments for Hemophilia B, Hemophilia A, X-Linked Severe Combined Immunodeficiency, and Myotubular Myopathy (XLMTM). He now directs the research group at Audentes, which develops AAV based therapies for severe monogenic diseases with unmet medical need.